Nutritional composition with low calorie and low protein content

专利摘要:

公开号:SE536599C2
申请号:SE1250357
申请日:2012-04-10
公开日:2014-03-18
发明作者:Bo Loennerdal；Olle Hernell；Lars-Boerje Sjoeberg；Catharina Tennefors
申请人:Hero Ag；
IPC主号:

专利说明:

536,599 infant formula on weight, weight in relation to height and BMI during the first two years of life. (B. Koletzko et al. Am J Clin Nutr, 2009; 89: 1836-1845.) Increased protein intake, which is the result of the use of the high-protein infant formulas on the market today, leads to higher insulin levels in infants. Infants who receive infant formula receive approximately 70% more protein than infants who are breastfed at the age of 3-6 months (M.J. Heinig et al. Am J Clin Nutr, 1993; 58: 152-156). Additional figures regarding the effect of an increased protein intake are also shown in a later European study. (Koletzko B. et al, Adv Exp Med Biol. 2oo5; 569: 69-79.) Children as a breast milk substitute also have a higher energy intake than children who are breastfed.
The reason why children who receive infant formula are at greater risk of getting too much energy in relation to their growth needs depends on fl your factors. Mothers who feed with ash have a greater tendency to "maternal control", ie. that the child can control his or her own intake to a lesser extent, compared to children who are breastfed (T. E. M. Taveras et al. Pediatrícs, 2004, vol. 114 (5) e577-e584) - In a study of cholesterol intake performed by Demmer T.A. et al. At the age of 4 months, the replacement-born children had a 40% higher energy intake than the children who were breastfed. (TAKE.
Demmers et al. Pediatrics, 2005, vol. 115 (6) 1594-1601). Increased “maternal control” has been shown to accelerate obesity in obese children and also increase the problem of underweight in children with difficulty gaining weight (C. Farrow et al. Pediatrícs, 2006, vol. 118 (2) e577-e584).
Children who were fed different breast milk substitutes with different energy contents seemed to be able to compensate for greater or lesser energy content to some extent by adjusting the amount of food ingested, but a higher energy content in breast milk substitute tends to increase baby calorie intake (SJ Fomon et al. J. Nutrition, 1969, 98: 241-254 and SJ Fomon et al. Acta Paediatr Scand 64: 172-181, 1975). There is great interest in these issues but only a few studies are available.
There are differences in morbidity between the infants who are breastfed and those who receive infant formula. Breastfed infants have fewer respiratory tract infections, ear infections, and gastroenteritis than infants receiving infant formula (A. Singhal et al. BMJ, vol. 299, 946-949; B. Duncan et al. Pediatrics, 2003, vol. 91 (5) 867-873, G.
Aniansson et al. Pediatr Infect Dís J, 1994, vol. 13 (3) 182-188 and K.G. Dewey et al. J Pediatrics, 1992, vol. 126 (No. 5) Part 1 695-702.) One possible explanation is that breast milk contains more immunomodulatory substances than cow's milk. 536 599 Sialic acid is found in milk both bound to proteins, for example kappa casein with its glycomacropeptide (cGMP) content, and lipid bound in gangliosides. Sialic acid is found in high concentrations in the human brain and breast milk, and has been presented as a milk factor that could affect the development of the central nervous system (B. Wang et al. Am J Clin Nutr, 2003; 57: 1351-1369). Enrichment with sialic acid in piglet diets has been shown to improve memory and learning (B. Wang et al. Am J Clin Nutr, 2007; 85: 561-569).
In addition, long-chain polyunsaturated fatty acids (LCPUFA) have a clear effect on the nervous system during its development. Breastfed infants have higher levels of arachidonic acid (ARA) and docosahexaenoic acid (DHA) in both blood and brain than children who received infant formula without supplementation of ARA and DHA (M. Makrides et al. Am J Clin Nutr, 1994; 60: 189- 94).
Dietary sphingomyelin is probably also important for the development of an infant's nervous system. In rat studies, it has been shown that enrichment with sphingomyelin in the diet increases the myelination of the nervous system (K.S.T. Oshida et al. Pediatr Res, 2003. 53: pp. 589-593).
Breast milk contains sphingomyelin.
With the help of new technology in the dairy industry, it is possible to separate new fractions of milk. An example of such a fraction is the "milk fat globule membrane" (MFGM), which comprises 120 different proteins in a double phospholipid layer which surrounds fat droplets in the milk. Sphingomyelin, phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine are the predominant phospholipids. Butyrophilin, MUC1 and PAS6 / 7 (lactadherin), CD14, TLR1 and TLR4 are examples of the dominant proteins that all have antimicrobiological effects (V. L. Spitsberg. J Dairy Sci, 2005. 88: pp. 2289-2294, T.A.
Reinhardt & J. D. Lippolis. J Dairy Res, 2006. 73 (4): pp. 406-416).
The cholesterol level in breast milk is much higher than in a conventional infant formula based on vegetable oil. The level in breast milk is about 10 mg / 100 ml and the level in breast milk substitutes on the market is about 0.2-1.0 mg / 100 ml. Therefore, breastfed infants have a much higher cholesterol intake than infants who receive infant formula.
This results in a higher blood cholesterol level in a baby who is breastfed during infancy. However, in older age,> 17 years, breastfed people show a lower blood cholesterol level, which is associated with a lower risk of developing cardiovascular disease compared to children who have received breast milk substitute (CG Owen et al. Am J Clin Nutr, 2008; 88: 305- 314, TA
Demmers et al. Pediatrics, 2005, vol. 115 (6) 1594-1601). The blood cholesterol level in infants depends not only on the food intake of cholesterol, but also on the effect of the endogenous synthesis of cholesterol. Studies in infants have shown that infants who receive infant formula, and who have low blood cholesterol levels, have an upregulated endogenous synthesis of cholesterol, compared to children who are breastfed. Perhaps this is an attempt to compensate for the low food intake. Despite this endogenous upregulation of cholesterol synthesis, infants receiving infant formula have lower blood cholesterol levels than breastfed infants. Attempts have therefore been made to add cholesterol to breast milk substitutes to mimic the level of breast milk and increase blood cholesterol levels in infants receiving breast milk substitutes (T.M. Bayley et al. Metabolism 2002; 5125-33).
To further illustrate this, Demmers et al. a clinical study in infants, where cholesterol was added to infant formula dissolved in ethanol to increase availability.
Blood cholesterol and fractional synthesis rate (FSR) were analyzed up to 18 months of age.
The results showed decreased endogenous cholesterol synthesis and increased concentration of cholesterol in circulating plasma at 4 months of age when the cholesterol ingested with the diet increased. But these differences did not show up at 18 months of age. The ratio of total cholesterol to HDL cholesterol at 4 months of age differed between the group that was breastfed and the group that received breast milk substitute cow's milk with cholesterol supplementation, indicating different cholesterol metabolism between the breastfeeding group and the cholesterol supplement group. As the study group was only followed up to 18 months, the long-term consequences of this are not known. Although the results confirmed from other studies that an increased cholesterol intake during the first months gives a higher total blood cholesterol level, both the importance of how the cholesterol is supplied and the long-term consequences of cholesterol levels in adulthood must be further studied. (T. A. Demmers et al.
Pediatrics, 2005, vol. 115 (6) 1594-1601.) Specific background There is a need for a nutritional composition or a breast milk substitute that gives the infant who is not breastfed, for example a growth pattern, a metabolic load and a blood cholesterol level similar to those for breastfed children and which at the same time reduces the risk for illness and ill health in infancy as well as later in life.
There is also a need for a manufacturing method for such a nutritional composition which has all the desired ingredients to provide a nutritional composition which provides the infants receiving the nutritional composition with similar growth and development patterns as breastfed infants. At the same time, there is a need for a production method for producing a nutritional composition that enables a good taste of such a nutritional composition, for example similar to the taste of breast milk.
There is a need to develop a breast milk substitute with reduced protein content and low energy content, which still covers the infant's need for amino acids and other nutrients. Prior art No prior art describes a nutrient composition according to the invention.
Several attempts have been made to create a breast milk substitute more similar to breast milk: Methods for producing low milk and high calorie breast milk substitutes are shown in EP1841330B1. However, the method described in EP184133oB1 does not contain a method for producing a breast milk substitute with increased levels of sialic acid and cholesterol, nor is it a breast milk substitute with a reduced energy content. US2oo8oo333o describes a method for creating a breast milk substitute with increased levels of sialic acid and phospholipids, but with a conventionally high level of proteins and standard levels of energy and cholesterol. The infant formula described in US2oo8oo333o uses MFGM supplements.
WO2007o73192 discloses a breast milk substitute in which the casein glycomacropeptide has been removed (cGMP). Breast milk substitutes with increased concentrations of ot-lactalbumin have also been presented to mimic the composition of breast milk but with a conventionally high level of protein and energy (e.g. E. L. Lien. Am J Clin Nutr, 2oo3; 77 (suppl): 1555S-1558S). The aim of the study described was to study the effects of infant formula with glycomacropeptide or ot-lactalbumin supplementation on growth, mineral status, iron, zinc and calcium absorption, as well as the concentrations of plasma amino acids, blood urea nitrogen and plasma insulin. Infants who were breastfed and infants who received infant formula enriched with α-lactalbumin had similar profiles of essential amino acids in plasma and insulin, which differed from those in infants who received glycomacropeptide or infant formula in the control group.
WO 2010/027258 A1 discloses a breast milk substitute containing a lipid component with larger lipid beads and wherein the protein source is for example based on acidic or sweet whey from which casein glycomacropeptide (cGMP) has been removed. The infant formula in WO 2010/027258 A1 preferably has a protein content of 1.25-1.35 g / 100 ml.
In previously developed breast milk substitutes, the cGMP content of the breast milk substitutes was reduced to reduce the amount of threonine (see, for example, WO2oo6o69918, page 4). Object of the invention The general object of the invention is to find a new nutritional composition, for example a breast milk substitute or a supplementary nutrient which results in the same or similar growth, development and morbidity as for children who are breastfed during the first months of life but also the same growth and development later in life when children become adults. There is a need for a nutritional composition which results in growth and development in infants who are not breastfed in a similar way as children who are breastfed, and which still does not unnecessarily burden the children's metabolic and kidney function, and which also resembles breast milk in taste. There is also a need for a production method for producing such a nutrient composition.
Summary of the invention Infant formula is intended, for example, to be used as the only food for infants who are not breastfed or as a supplement for children who are partially breastfed, or as part of the diet after weaning. In order to fulfill this, the product must cover your baby's different nutritional needs. It was therefore a great challenge to formulate a correct nutritional composition according to the invention.
The challenges known to those skilled in the art, but which are not currently satisfactorily addressed, are: protein content and protein quality, energy content, essential fatty acid content, medium chain fatty acid (MCT) content, content of sialic acid, gangliosides, sphingomyelin, and the content and quality of cholesterol in infant formulas on the market today. According to the present invention, it has surprisingly been possible to improve all these parameters without at the same time adversely affecting the overall composition of the product.
Protein quantity and protein quality: There must be a sufficient amount of protein, but not too high a level (as stated above) and the protein quality must be such that it is easily broken down by the infant and meets the infant's amino acid needs with as little protein as possible. Since the amino acid requirement must be absolutely met, it has previously been forced to add an excess of protein due to the composition of the protein sources used. There was therefore a need to invent a product which with a lower protein level could meet the amino acid requirement. At the same time, it is important to keep the non-protein nitrogen (N PN) at a low level. All this is achieved with the nutritional composition and production method of the present invention. 10 15 20 25 30 35 536 599 Energy content: It is well known that infants who are given a standard infant formula show a faster weight gain than children who are breastfed. This is due to fl your factors: a higher protein intake, a higher calorie intake due to a higher energy content in the infant formula and possibly a less developed self-regulation of calorie and volume intake. Since part of the total amount of carbohydrates in breast milk (the oligosaccharides) is not used as an energy source and the lactose content in infant formula was previously considered the same as the total carbohydrate content in breast milk including the oligosaccharides, the lactose content in the nutritional composition is now corrected. with reduced energy content (kcal / 100 ml).
No one has previously developed a product where both protein content and calorie content are reduced, and where all other nutrients are still at the desired levels. In the present invention, such a infant formula has been developed. The nutritional composition of the invention has been tested in a clinical study and the growth of the infants using the nutritional composition of the invention was similar to that of breastfed infants.
The study thus shows that the content of energy and amino acids was satisfactory.
Phospholipids, sphingomyelin, sialic acid, gangliosides are all nutrients that are recognized as important nutrients for the baby. The challenge has been to be able to incorporate suitable sources of these nutrients into the composition of infant formulas without adversely affecting other important nutrients and the general composition of the product. In the present invention, this incorporation has taken place to levels close to the level in breast milk without any adverse effect on the overall composition.
Cholesterol is also widely considered as an important component of infant formula.
However, to date, no method has been developed to include available cholesterol in the product so that it is well absorbed and metabolized. The addition of free cholesterol has been tested in previous studies, but there are questions about its availability, metabolism and protection against oxidation during production. In the present invention, this has been solved by the addition of cholesterol-rich raw materials, without adverse effect on other important parameters.
Other important ingredients such as essential fatty acids, long chain fl unsaturated fatty acids, triglycerides with medium fatty acids, minerals, vitamins have all been added as carefully selected raw materials.
The result of the invention is a infant formula where all the above requirements have been met, without compromising ingredients in the general composition of the product. A clinical study is being carried out with a breast milk substitute according to the invention, where the goals of the invention are verified. The overall goal of the nutritional composition, for example a infant formula according to the invention, is to achieve a result similar to that of infants who are breastfed with respect to the development of infants receiving the composition of the invention, rather than providing a infant formula with ingredients at similar levels as in breast milk.
The production method according to the invention, i.e. the careful selection of ingredients in the amounts described according to the invention is not an obvious choice for a person skilled in the art. Surprisingly, the choice of ingredients at the present levels according to the invention means both that the infant formula meets the nutritional requirements of the authorities and at the same time, thanks to the special choice of composition, that infants receiving the nutritional composition of the invention develop more like breastfed infants. Finding a nutritional composition that allows the infant who receives infant formula also to have a neurological development as an infant who is breastfed is a known problem that has so far remained unresolved. A nutrient composition has been developed which has a low protein content and a low energy content, and this is combined with a high content of milk phospholipids as well as sialic acid and cholesterol, and further in combination without the addition of free amino acids. The infant formula according to the invention has a low protein content, expressed in g / 100 ml, but still a low energy percentage protein (E% protein) compared to standard infant formula despite the reduced energy content of the infant formula.
This nutritionally complete infant formula will help make the baby's development in terms of growth, body composition, metabolic parameters, morbidity and neurological development more similar to that of breastfed infants.
Parameters that are affected by the use of infant formula according to the invention are, for example, growth, body composition (% fat), blood cholesterol, blood urea nitrogen (BUN), sialic acid in saliva, fasting insulin, blood pressure, short-term morbidity, immunological parameters, neurological parameters and micro fl parameters. . Long-term parameters are, for example, reduced obesity and morbidity during both childhood and adulthood. The infants who receive the nutritional composition according to the invention surprisingly develop in a way that is closer to the development of infants who are breastfed.
A nutritional composition according to the invention achieves the objects of causing the infant given the composition to grow and develop in the same manner as the infant being breastfed.
Using the nutritional composition during the first 6 months of life as the only source of nutrition, or from birth to 12 months of age as a supplement to the food can, for example, minimize the difference in growth and / or body composition (weight percent fat) and / or cholesterol levels and / or blood urea levels and / or plasma amino acids and / or sialic acid in saliva and / or the levels of fasting insulin and / or morbidity and / or parameters and / or prevalence of childhood obesity between breastfed infants and those receiving infant formula in combination with the nutritional composition of the invention does not unnecessarily burden the metabolic system of non-breastfed infants.
Previously, infant formulas were made using whey protein concentrate from which cGMP was removed. Surprisingly, due to the particular choice of ingredients in the composition of the invention, cGMP does not need to be removed, and this facilitates the presence of high sialic acid levels in the nutritional composition of the invention. In the infant formula according to the invention, the threon content is not too high.
The amino acid levels of the infant formula are in accordance with the requirements of Commission Directive 2006/141 / EC and the infant formulas are also within the range of protein and energy content specified in the Directive. No one has previously produced a breast milk substitute with both low protein and low energy content, which in combination with this has a high sialic acid content and a high content of milk cholesterol. There is nothing in the literature that can instruct the person skilled in the art how such a breast milk substitute could be produced. Because there are so many different parameters to consider, it is not clear how to compile a infant formula that meets both the infant's needs and the Commission's directives, national laws and recommendations in the field of pediatric nutrition.
The object of the invention is not to be as similar to breast milk as possible in composition, but that the infants who are given the infant formula according to the invention should develop as similar as possible to breastfed children. Uptake and availability of nutrients differ between infant formula and breast milk.
The infants have a growth and development that is more similar to infants who are breastfed when they are given the infant formula according to the invention.
Various embodiments of the invention are shown below; the embodiments are exemplary embodiments and do not limit the scope of the invention.
In one embodiment of the invention, the nutritional composition according to the invention comprises: a total energy content of 62 kcal / 100 ml or less, or for example less than 60 kcal / 100 ml or 58-62 kcal / 100 ml or for example 58-60 kcal / 100 ml, 536 599 - a protein content of 1.25 g / 100 ml or less, or for example less than 1.25 g / 100 ml or for example 1.1-1.25 g / 100 ml or between 1.1 g / 100 ml and less than 1.25 g / 100 ml.
In an embodiment of the invention, the nutritional composition according to the invention has a total energy content of 62 kcal / 100 ml or less and the composition comprises: - a protein content which is 1.25 g / 100 ml or lower, - a cholesterol content of 5-10 mg / 100 ml .
In an embodiment of the invention, the nutritional composition according to the invention has a total energy content of 62 kcal / 100 ml or less and the composition comprises: - a protein content which is 1.25 g / 10 ml or lower, - an energy content from protein of 7.8-8 , 4% of the total energy content of the nutritional composition, - an energy content from fat which is at least 50% or more of the total energy content of the nutritional composition, - a content of fatty acids with medium carbon chains comprising 8 to 10 carbon atoms which is less than 3% by weight of total fatty acids, a sialic acid content of 10-25 mg / 100 ml or higher, - a cholesterol content of 5-10 mg / 100 ml.
In another embodiment of the invention, the nutrient composition according to the invention comprises: a total energy content of 62 kcal / 100 ml or less, or for example less than 60 kcal / 100 ml or 58-62 kcal / 100 ml or for example 58-60 kcal / 100 ml , - a protein content of 1,25 g / 100 ml or less, or for example less than 1,25 g / 100 ml or for example 1,1-1.25 g / 100 ml or between 1,1 g / 100 ml and less than 1.25 g / 100 ml, 10 10 15 20 25 30 536 599 - an energy content from protein of 7.8-8.4 percent of the total energy content of the nutrient composition or, for example, 8.0-8.3 percent of the total energy content of the nutrient composition, a fat content which is at least 50 percent or more of the total energy content of the nutrient composition or for example 52-53 E% fat; for example, 52.5% of the energy of the infant formula comes from fat, - a content of fatty acids with medium carbon chains comprising 8 to 10 carbon atoms which is 0.5-3% by weight of the total amount of fatty acids or for example 1-3% or for example 1-2% of the total amount of fatty acids in the composition, - sialic acid content of 18 mg / 100 ml or higher, or 18-25 mg / 100 ml, - a cholesterol content of 5-10 mg / 100 ml or 7-10 mg / 100 ml or for example o , 2-o, 3% by weight of cholesterol expressed as a percentage of the total fat content in the infant formula or, for example, 8 mg / 100 ml, which is 0.23% by weight of cholesterol expressed as a percentage of the total fat content in the infant formula.
In another embodiment of the invention, the nutrient composition according to the invention further comprises - lipid-bound sialic acid as gangliosides with 1.5-5% by weight of the total sialic acid content, or for example 4% by weight of lipid-bound sialic acid of the total sialic acid content.
In one embodiment of the invention, the energy content of the nutrient composition according to the invention is, for example, 58-60 kcal / 100 ml, of which 51.8-53.4 E% fat. The protein content is, for example, 1.1-1.25 g / 100 ml and 7.8-8.2 E% protein, and a low NPN content is, for example, an NPN content of 0.015-0.020 g / 100 ml and a high sialic acid content is for example 18-20 mg / 100 ml. The content of milk cholesterol is, for example, 7-9 mg / 100 ml.
In another embodiment of the invention, the energy content of the nutrient composition according to the invention is 60 kcal / 100 ml, and the composition comprises 52.5 U% fat.
The protein content is 1.2 g / 100 ml and the composition comprises 8 U% protein. In another embodiment of the invention, the energy content of the nutritional composition of the invention is 60 kcal / 100 ml and 52.5 U% fat, the protein content is, for example, 1.2 g / 100 ml and the composition comprises 8 U% protein, with a non-protein nitrogen ( NPN-) content of 0.015-0.020 g / 100 ml or for example 0.016 g / 100 ml, and a high sialic acid content is 536 599 for example 19 g / 100 ml. The content of milk cholesterol is, for example, 8 mg / 100 ml and the composition comprises a content of fatty acids with medium carbon chains (comprising 8 to 10 carbon atoms) which is less than 3% by weight of the total amount of fatty acids.
A nutritional composition according to the invention, or the use according to the invention, may also refer to the composition of the invention as a powder suitable for preparing a surfactant composition after reconstitution with water.
The nutritional composition of the invention can be prepared from powder by mixing 114 g of a nutritional composition powder with 900 ml of water to prepare 1000 ml of surfactant composition according to the invention.
The nutritional composition of the invention further comprises the following details in any combination: In other embodiments of the invention, the infant formula comprises 5-6% by weight of whey protein concentrate dry substance rich in phospholipids and 12-15% by weight of cream dry matter expressed as a percentage of dry powder in the composition.
In an embodiment according to the invention, the infant formula further comprises a sphingomyelin content in the infant formula of 10 mg / 100 ml or higher, for example 9-15 mg / 100 ml, for example 13 mg / 100 ml.
Further embodiments are also alternative embodiments of the invention: A nutritional composition according to the present invention wherein the composition comprises intact or partially hydrolyzed milk protein.
A nutritional composition according to the present invention wherein the amino acid content of the composition is derived from sources selected from, for example: sweet whey powder, casein powder, milk powder and cream powder.
A nutritional composition of the present invention wherein the sangomyelin content of the composition of the invention is 10 mg / 100 ml or higher, or 9-15 mg / 100 ml, or 13 mg / 100 ml.
A nutritional composition according to the present invention wherein the composition comprises the following ingredients: dry matter from sweet whey, 32-40 kg / 1,000 kg dry powder composition or 32.6-39.9 kg / 1,000 kg dry powder composition, sodium caseinate, 4.6-5.7 kg / 1,000 kg dry powder composition or 4.66-5.69 kg / 1,000 kg dry powder composition, - skimmed milk powder, 66-81 kg / 1,000 kg dry powder composition or 66.3-81 kg / 1,000 kg dry powder composition, - whey protein concentrate dry substance rich in phospholipids, 47-58 kg / 1,000 kg dry powder composition or 47.1-57.6 kg / 1,000 kg dry powder composition, - cream dry substance, 117-143 kg / 1,000 kg dry powder composition.
A nutritional composition according to the present invention wherein the composition comprises: dry whey dry matter with 36.3 kg / 1,000 kg dry powder composition, sodium caseinate with 5.18 kg / 1,000 kg dry powder composition, skim milk dry matter with 73.7 kg / 1,000 kg dry powder composition, whey powdery mildew protein 52.4 kg / 1,000 kg dry powder composition, cream dry substance with 130 kg / 1,000 kg dry powder composition.
A nutritional composition according to the present invention wherein the above-described values defining the ingredients of the composition in kg / 1,000 kg of powder are the same when defining the ingredients of the composition in kg / 8,770 l of ready-to-drink nutritional composition.
Furthermore, the composition may include vitamins (see for example the vitamins mentioned for composition A below), minerals (see for example the minerals mentioned for composition A below), fats (see for example the fats mentioned for composition A below or in the detailed description) , lactose and / or other essential nutrients (eg choline, taurine, inositol, carnitine, fructooligosaccharides (FOS), galactooligosaccharides (GOS), probiotics or nucleotides).
Furthermore, the nutritional composition according to the invention may comprise smaller amounts of other ingredients, for example less than 7% by weight of the total weight of the infant formula. Examples of such other ingredients are other milk dry substance (not in the specified infant formula), for example whey protein concentrate from sour whey, buttermilk powder, whole milk powder, etc. Said other ingredients may be included as long as the specification of the nutritional composition, as described above, according to the invention, is realized. A nutritional composition according to the present invention wherein the composition comprises: dry whey dry matter with 36.3 kg / 1,000 kg dry powder composition, sodium caseinate with 5.18 kg / 1,000 kg dry powder composition, skim milk dry matter with 73.7 kg / 1,000 kg dry powder composition, whey protein concentrate dry substance rich in phospholipids with 52.4 kg / 1,000 kg dry powder composition, cream dry substance with 130 kg / 1,000 kg dry powder composition. Furthermore, the composition may include vitamins (see for example the vitamins mentioned for composition A below), minerals (see for example the minerals mentioned for composition A below), fats (see for example the fats mentioned for composition A below), lactose and / or other essential nutrients (eg choline, taurine, inositol, carnitine).
Furthermore, the nutritional composition according to the invention may comprise other ingredients as long as the specification of the nutritional composition, as described above, according to the invention, is realized.
Use of a composition according to the present invention as a nutritional composition or as a infant formula or as a supplementary nutrient.
Use of a nutritional composition according to the present invention as a nutritional composition to provide a developmental and / or growth pattern and / or morbidity more similar to data for breastfed infants and / or regarding parameters which are one or more of growth, body composition in weight percent fat, cholesterol level , blood urea nitrogen (BUN), salivary sialic acid, levels of fasting insulin or decreased obesity and / or disease incidence during childhood.
Furthermore, the production method of the invention is described according to the following embodiments: A method for preparing a nutritional composition according to the present invention for obtaining a high sialic acid content and a high cholesterol content in combination with a low protein and energy content, comprising the following steps: - to provide ingredients per 1,000 kg dry powder or per 8 770 l ready-to-drink nutritional composition, - sweet whey powder, 32-40 kg / 1 000 kg dry powder composition or per 8 770 l ready-to-drink nutritional composition, - sodium caseinate, 4.6-5.7 kg / 1 000 kg dry powder composition or per 8 770 l ready-to-drink nutritional composition, - skimmed milk dry matter, 66-81 kg / 1,000 kg dry powder composition or per 8 770 l ready-to-drink nutritional composition, 14 10 15 20 25 30 536 599 - whey protein concentrate dry substance rich in phospholipids, 47-58 kg / 1,000 kg dry powder composition or per 8 770 l nutritional composition , - cream dry substance, 117-143 kg / 1 000 kg dry powder composition or per 8,770 l of ready-to-drink nutritional composition, - in addition further comprising, for example, vitamins, minerals, fats, lactose and other essential nutrients (eg choline, taurine, inositol, carnitine), and - mixing the ingredients.
A method of preparing a nutritional composition according to the invention wherein no free amino acids are added in addition to naturally occurring free amino acids found in dairy raw materials.
It is further possible to add small amounts of other ingredients to the composition according to the invention as long as the specification of the nutritional composition, as described above, according to the invention is realized. For example, whey powder from acid whey can be used.
A method according to the present invention for preparing a nutritional composition according to the invention wherein no free amino acids are added in addition to the additions which take place by adding raw materials from sources selected from: whey powder from sweet whey, casein powder, milk powder and cream powder.
Detailed Description Introduction The general object of the invention is to find a nutritional composition, for example a breast milk substitute, which generates growth and development, in the short and long term, in non-breastfed children, in a similar way as in breastfed children.
The growth and development of the infants given the nutritional composition of the invention is similar to the growth and development in the short and long term for breastfed children and this without unnecessarily straining the infants' metabolism due to overloading of nitrogen sources, for example protein in excessive amounts.
A nutritional composition according to the invention is, for example, a breast milk substitute which is defined as a food intended for infants from birth and during the first 6 months of life, and as the only prepared food meets the nutritional requirements of this group. Furthermore, for example, the nutritional composition according to the invention may be intended to be used as a supplementary nutrient which is defined as a supplement or as part of an increasingly diversified diet in which the intake of infant formula begins, for example, when the infant is 4 months old and ingested by Breast milk replacement is then part of the infant's diet until it is 12 months old. The infant can begin to include the infant formula according to the invention at the age of 4-6 months, which is the time when most infants start with solid foods, or at least when the nutritional intake of the breastfed infant is supplemented with solid foods from 6 months up to 12 months of age. . A nutritional composition according to the invention may be, for example, a breast milk substitute or a supplementary nutrient. The nutritional composition according to the invention can also be called “a breast milk substitute” or “a composition”.
A infant formula is a composition intended to be used as the sole source of nutrients from birth to 6 months of age, and a supplementary nutrient can be defined as a composition intended to be used from 6 months onwards during the weaning period, as a supplement to the solid food that introduced into the infant's diet at the same age.
A nutritional composition, also called a infant formula according to the invention, is for example a powder intended to be mixed with water before use or a ready-to-use product.
The term "ready-to-use product" as used in this preparation refers, unless otherwise indicated, to fl peripheral infant formulas suitable for direct oral administration to an infant; products manufactured ready for consumption, powder reconstituted with water or water added to a concentrate ready for consumption.
The fi nition of an infant is a child younger than 12 months.
The solution to the above problem is a nutritional composition according to the invention which minimizes the difference in growth and insulin levels between breastfed and non-breastfed infants.
A nutritional composition according to the invention has a low energy content in combination with a low protein content. A nutritional composition according to the invention is more nutritionally complete and includes mj your milk raw materials including sweet whey, whey protein concentrate rich in phospholipids, cream rich in cholesterol and also includes glycomacropeptide (cGMP) which allows higher sialic acid content. Another important factor of the present invention is that it may further have a low content of non-protein nitrogen (NPN). 16 10 15 20 25 30 536 599 There are fl your reasons why children who are not breastfed are at greater risk of getting too much energy in relation to their growth needs. Increased protein intake leads to higher insulin levels and infants receiving conventional infant formula receive approximately 70% more protein than infants breastfed between 3 and 6 months of age (M.J. Heinig et al. Am J Clin Nutr, 1993; 58: 152-156). (B. Koletzko et al. Am J Clin Nutr, 2oo9; 89: 1836-1845.) Mothers who give infant formula have a greater tendency to "maternal control", ie. that the child has less control over their own intake, compared to children who are breastfed (EM Taveras et al. Pediatrics, 2004, vol. 114 (5) e577-e584, and RS Gross et al. Academic Pediatrics, 201o; 10: 29- 35, and L. Ruowei et al. Pediatrics, 2008; 122: S77-S85).
The effect of increased “maternal control” has been twofold: accelerated obesity for overweight children, but also increasing problems with underweight children (C. Farrow & J. Blissett. Pediatrics, 2006, vol. 118 (2) e293-e29). There are also some studies that have shown that young infants can down-regulate food intake, depending on the energy content of the infant formula (S. J.
Fomon et al. J. Nutrition, 1969, 98: 241-254 and S. J. Fomon et al. Acta Paediatr Scand 64: 172-181, 1975).
The infant formula according to the invention includes low level of protein and also low level of total energy content.
Energy content The produced infant formula has an energy level of, for example, 62 kcal / 100 ml or less, or for example less than 60 kcal / 100 ml or 58-62 kcal / 100 ml or for example 58-60 kcal / 100 ml. These selected energy levels are at the lowest level according to Commission Directive 2006/141 / EC. The report of the "Scientific Food Committee on the change of essential requirements for infant formula and supplementary nutrition" emphasizes that an energy intake below the recommended intake does not mean that this intake for an individual is insufficient and can be harmful to the person in question. The developed infant formula has a lower energy content than conventional infant formulas and is nutritionally complete and meets the nutritional needs of a rapidly growing infant during the first year of life.
Since part of the total carbohydrate content of breast milk (the oligosaccharides) is not used as an energy source and the lactose content of infant formula was previously considered the same as the total carbohydrate content of breast milk including oligosaccharides, the lactose content of the invention is reduced. energy content (kcal / 100 ml).
Protein content 17 10 15 20 25 30 536 599 Furthermore, the infant formula according to the invention has a low protein level in g / 100 ml, but still a low energy percentage (E%) compared to a standard infant formula.
The nutritional composition of the invention has 7.8-8.4 E% protein or for example 8.0-8.3 E% protein.
The protein content of the ready-to-drink nutritional composition is, for example, 1.25 g / 100 ml or less or, for example, less than 1.25 g / 100 ml or, for example, 1.1-1.25 g / 100 ml or between 1.1 g / 100 ml and less than 1.25 g / 100 ml.
Fat content The produced infant formula also has a high E% fat (derived) from fat.
The fat content of the nutrient composition according to the invention constitutes at least 50% or more of the total energy content of the nutrient composition, for example fat constitutes 50-54% or for example 52-53%, or for example 51.8-53.4% of the total energy content of the nutrient composition.
Fat is essential in the diets of infants and toddlers due to their extraordinary energy needs and limited dietary capacity. In addition, various fat sources provide fl unsaturated essential fatty acids such as linoleic and linolenic acids as well as long chain fl unsaturated essential fatty acids such as arachidonic acid and docosahexaenoic acid.
Lack of these long-chain polyunsaturated fatty acids in the diet during infancy can affect the central nervous system maturation process, including vision development and intelligence (see, e.g., E. E. Birch et al. Early Hum Dev, 2007, Vol. 83, 279-284, and M. S. Kramer et al.
Arch Gen Psychiatry, 2008; 65 (5): 578-584).
The nutritional composition of the invention further comprises, for example, 0.43-0.47% or, for example, 0.45% arachidonic acid (ARA) (n-620: 4) and, for example, 0.26-0.30% or, for example, 0.28% docosahexaenoic acid ( DHA) (n-3 22: 6) of the total amount of fatty acids.
To obtain these fatty acids in these percentages and ratios, raw material from algal oil and mushroom oil a is used. Furthermore, the invention's infant formula may include rapeseed oil, palm olein oil a, sunflower oil and sunflower oil with a high oleic acid content to provide a fatty acid pattern similar to that in breast milk. The sunflower oils mainly contribute with the essential fatty acid linoleic acid (n-6 18: 2). Rapeseed oil contributes mainly with the essential fatty acid linolenic acid (n-3 18: 3). Other oils that can also be used are: rapeseed oil (high oleic acid content), soybean, corn, thistle, giant evening primrose, borage, palm, palmolein, palm kernel, coconut, babassu and fish oil, egg lipids, structured fat with high percentage of palmitic acid esterified to ß-position in the triglycerides and lard. To even better mimic the fat composition in breast milk, cream is used. The use of cream as an ingredient in the present nutritional composition (or the use of cream powder in the preparation of a nutritional composition powder to be mixed with water) contributes to the high levels of milk cholesterol in the nutritional composition of the invention. This use of cream contributes to the high levels of cholesterol (5-10 mg / 100 ml) in the composition of the invention. Due to the special composition of the invention, the addition of cholesterol as an ingredient (due to the addition of cream and whey protein concentrate rich in phospholipids) gives a blood cholesterol level similar to that of infants who are breastfed during the breastfeeding period but also later in life for the infants given the nutritional composition according to the invention.
The cream also improves the taste of the infant formula. The infant formula can also contain whey protein concentrate rich in phospholipids, which also contributes to the content of both milk cholesterol in the infant's infant formula and the milk phospholipid sphingomyelin. The infant formula of the invention comprises, for example, 30-32% by weight of fat in powder or, for example, 30.7% by weight of fat in powder of which 18-19% by weight of the total amount of fat is vegetable fat, or for example 18.5% by weight of the total fat content is vegetable fat.
The content of medium chain fatty acids (MCT) containing 8 to 10 carbon atoms in the nutritional composition of the invention is, for example, 0.5-3% by weight of the total amount of fatty acids or, for example, 1-2% by weight of the total amount of fatty acids in the composition. The infant formula of the invention mimics the content of MCT in breast milk. Matured breast milk has 1-2% MCT of the total fatty acid content (R.A. Gibson et al. Am. J. Clin. Nutr. 34: 252-257, 1981).
The use of sweet whey, cream and whey protein concentrate rich in phospholipids, in the preparation of the nutritional composition or infant formula of the present invention, causes the nutritional composition to comprise a large amount of sialic acid and milk phospholipids. The nutritional composition may, for example, comprise a sialic acid content of 10 mg / 100 ml or higher or 18 mg or higher or, for example, a sialic acid content of 10-25 mg / 100 ml or 18-25 mg / 100 ml. For example, whey powder from sweet whey, cream powder and whey protein concentrate powder rich in phospholipids can also be used to prepare a powder composition according to the invention which is intended to be mixed with water before use. The use of these raw materials or ingredients also means that the nutritional composition according to the invention comprises lipid-bound sialic acid as gangliosides with 1.5-5% of the total sialic acid content or for example 4% of the total sialic acid content. Said lipid-bound sialic acid content, as gangliosides, in the infant formula according to the invention is 0.03-0.08% by weight of the total fat content in the infant formula or, for example, 0.05% by weight of the total fat content in the infant formula.
Gangliosides stimulate the maturation process of the intestines and promote a normal micro fl ora as well as the development of the nervous system and brain. Sialic acid plays a role in cognitive development and can protect against intestinal infection.
Furthermore, the infant formula according to the invention comprises cholesterol, which is a sterol which is mainly synthesized in the liver but also in other tissues. It is used to produce hormones in cell membranes and is transported in the blood plasma of all mammals.
Breast milk contains cholesterol. Through the use of cream and whey protein concentrate rich in phospholipids as raw materials, the cholesterol content of the produced infant formula is high, similar to the level in breast milk.
The nutritional composition according to the invention has a cholesterol content of 5-10 mg / 100 ml, or 7-10 mg / 100 ml or for example 8 mg / 100 ml, which is for example 0.2-0.3% by weight of the total fat content in the nutritional composition or e.g. 0.23% by weight of the total fat content of the nutritional composition of the invention.
Furthermore, both sweet whey, cream and whey protein concentrate rich in phospholipids contain cGMP. For example, by not removing cGMP from the nutritional composition of the invention, the sialic acid content is kept high. The high sialic acid content is, for example, about 10-25 mg / 100 ml or 18-20 mg / 100 ml of the nutrient composition according to the invention.
Because cGMP is not removed from the raw materials used to make the infant formula, the nutritional composition of the invention is likely to increase, for example, the level of sialic acid in saliva (more like breastfed babies), which may have an effect on, for example, morbidity and cognitive development in infants. infant formula.
Singomyelin is the major component of the phospholipid fraction in breast milk, and is found in lower concentrations in conventional nutritional compositions compared to the infant formula of the invention. Songomyelin is metabolized to ceramide, the concentration of which correlates with the degree of myelination of the nervous system. Experiments with rats with experimentally inhibited myelination have shown that sphingomyelin administration increases the myelination (K. Oshida et al. Pediatr Res, 2003, v01. 53 (4) 589-593). The content of sphingomyelin from dairy raw materials in the infant formula according to the invention is 9 mg / 100 ml or higher, or 9-15 mg / 100 ml, or 13 mg / 100 ml.
The nutritional composition according to the invention comprises a special composition of raw materials. The nutritional composition of the present invention has a low load on the metabolism of the infant receiving the supplement even though it comprises cGMP.
The levels of arachidonic acid (ARA) and docosahexaenoic acid (DHA) in the nutritional composition of the invention are similar to the levels in breast milk.
The present invention provides a nutritional composition and a method of preparing such a composition.
Non-protein nitrogen (NPN) is a term used to denote non-protein, food-containing and nitrogen-containing components. (NPN in milk is mainly urea nitrogen (about 50%), creatine, creatinine, NH3, etc.).
Since it is important not to have an excess of nitrogen in infant formula, we have tried to get a low level of NPN <20 mg / 100 ml in the nutritional composition of the invention, for example a low value of non-protein nitrogen (NPN) of 0.015-0.20 g / 100 ml. Surprisingly, the infant formula of the invention has a low NPN value even though it has a completely new composition of raw materials.
Amino acid profile It is known that a breast milk substitute needs a predetermined amino acid profile to meet the needs of children. This is also governed by Commission Directive 2006/141 / EC.
The supply of amino acids during the first months of an infant must be sufficient in both quantity and quality to meet the needs during this period. Guidelines, recommendations with minimum values have been established with regard to the amino acid composition of infant formula. An amino acid profile of the nutrient composition of the invention is presented in the table below. The clinical study confirms that the amino acid composition of the infant formula meets the requirement for growth. 21 536 599 Amino acid Minimum value Interval according to the invention _ _ (mg / 100 kcal) Commune Directive (mg / 100 kcal) Leucine 166 197-229 or 217 Lysine 113 165-192 or 180 Methionine 23 36-42 or 40 Cystine 38 40-46 or 44 Phenylalanine 83 83-96 or 87 Tyrosine 76 64-74 or 72 Threonine 77 114-132 or 124 Tryptophan 32 35-41 or 39 Valine 88 116-135 or 127 Isoleucine 90 116-135 or 127 22 10 15 20 536 599 Histidine 40 46-53 or 50 Cystine + methionine * 61 76-88 or 84 Phenylalanine + tyrosine * 159 147-170 or 159 The concentration of methionine and cysteine can be calculated together because the amino acid cysteine can be formed by methionine. And the concentration of tyrosine and phenylalanine can be calculated together because the amino acid tyrosine can be formed by phenylalanine. Therefore, the combined levels of these amino acids are also listed in the table above *.
Amino Acid Sources of the Present Nutrition Composition: The infant formula of the invention has a composition such that the desired amino acid profile is obtained without the addition of any free amino acid. The infant formula of the invention is prepared without the addition of any free amino acid (or isolated amino acids) to obtain a desired amino acid profile.
The term free amino acids or isolated amino acids in this patent application refers to descriptions of an amino acid substance which is isolated as a free acid or as a salt.
The infant formula of the present invention is therefore m3 enriched with isolated amino acids, for example free amino acids. This is an advantage because free amino acids often have a bitter taste. It is also expensive to add amino acids in pure form. By using the ingredients of the present invention, the nutritional composition of the invention does not require additional addition of free or isolated amino acids and is therefore more similar to breast milk in taste.
Method of preparation The infant formula according to the invention is prepared according to one embodiment by mixing the ingredients below in kg per 1000 kg of dry powder nutrition composition or kg per 8,770 l of finished nutritional composition. 23 10 15 536 599 Raw material Interval in infant- Quantity in infant formula milk substitute- according to the invention according to (kg / 1,000 kg powder yield or kg / 8,770 l) (kg / 1,000 kg powder or kg / 8,770 l) Dry matter from sweet whey 32-40 36 in 2 Sodium caseinate 4.6-5.7 5.2 in 0.3 Skimmed milk dry substance 66-81 74 in 4 Whey protein concentrate- 47-58 52 in 3 dry substance (rich in phospholipids) Cream dry substance 117-143 130 i The nutritional composition may further comprise vitamins, minerals, fats, lactose and / or other essential nutrients (for example choline, taurine, inositol, carnitine, nucleotides).
Furthermore, the nutrient composition according to the invention may comprise other ingredients as long as the specification of the nutrient composition, as described above, according to the invention, is realized.
Whey protein concentrate powder (rich in phospholipids) Whey protein concentrate powder rich in phospholipids, which is used as a component in the nutritional composition of the invention, is a whey protein concentrate with a high concentration of bioactive proteins and lipids. The whey protein concentrate has a high nutritional value and can be used as nutrition for infants and in clinical treatment.
Whey protein concentrate powder rich in phospholipids contains most of the insoluble membrane protein fragments from MFGM that were originally present in whey, along with residual whey components, proteins, lactose and salts. The invention utilizes whey protein concentrate powder rich in phospholipids which is obtained after removal of the major whey proteins by known industrial processing, such as filtration, ion exchange chromatography and the like. This fraction contains most of the insoluble membrane fragments, which contain protein and associated fats.
Whey protein concentrate powder rich in phospholipids contains bioactive compounds such as lactoferrin, α-lactalbumin, butyrophilin, MUC1, PAS6 / 7 (lactadherin), gangliosides, CD14, TLR1 and TLR4, IgG, cGMP, folicosylic acid, ). Phospholipids are important components of cell membranes and contribute greatly to the structure and function of membranes.
Lacprodan MFGM-10 (from Arla Foods) or similar raw materials from other suppliers can be used as enriched phospholipid whey protein concentrate powder in a breast milk substitute according to the invention. For example, the enriched phospholipid whey protein concentrate powder contains at least 20% by weight of phospholipids based on the total lipid content, for example 20 to 70% by weight or for example 25 to 55% by weight of phospholipids based on the total lipid content of the enriched phospholipid whey protein concentrate. cGMP has not been removed in the whey protein concentrate powder rich in phospholipids, which is used in the nutritional composition of the present invention.
The components of whey protein concentrate powder rich in phospholipids can positively affect the development of the nervous system, morbidity and psychomotor development in infants given the nutritional composition of the invention compared to infants given the standard infant formula or control composition of the invention.
Whey protein concentrate powder rich in phospholipids from cow's milk contains unique polar lipids and membrane-specific proteins, for example lactoferrin, butyrophilin, MUC1 and PAS6 / 7 (lactadherin), CD14, TLR1 and TLR4 as well as phospholipids (including eg sphingosine). These nutritional and bioactive milk constituents are recognized as important and are present only in small amounts in cow's milk compared to breast milk.
Whey protein concentrate powder contains gangliosides, sialic acid, sphingomyelin, phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, lactoferrin, α-lactalbumin, etc.
Sweet whey Sweet whey is rich in oL-lactalbumin. The high content of α-lactalbumin makes it ideal as a protein source in infant formulas to achieve the desired amino acid pattern.
Sweet whey also contains cGMP, which is a source of sialic acid. 25 10 15 20 25 536 599 Cream Cream is a natural and valuable source of fatty acids with short and medium carbon chains and milk cholesterol. In addition to important nutrients, the phospholipids in cream are also valuable emulsifiers. The infant formula according to the invention can be made with cream or cream powder. The fat content of the cream used according to the invention is, for example, 36-40% by weight of fat or 37% by weight of fat.
Caseinate Atrium caseinate or partly other salts of caseinates can be used in the formula's infant formula.
Hydrolyzed protein The source of protein in the invention's infant formula may be a hydrolysed protein.
Below is an exemplary description of the manufacturing process for the infant formula according to the invention; The following examples of the invention do not limit the scope of the invention: The present invention provides a ready-to-drink nutritional composition or a powdered infant formula intended to be reconstituted with water into a ready-to-drink nutritional composition, and a method of preparing such compositions.
In one embodiment, the composition is a powder suitable for creating a surface composition after reconstitution with water. Or the composition is, for example, a fl surface product ready to use.
Below is an example of ingredients for creating the nutritional composition of the invention.
Examples of quantities of ingredients fl kgl 1,000 kg! to a powdered infant formula according to the invention which is intended to be reconstituted with water before use quantities of ingredients for the potency of the infant formula are described below in kg / 8 7701): Quantity Description (range) (kg / 1 ooo kg 26 536 599 or kg / 8 770 l) Lactose 476-527 Cream dry substance 123-136 Skimmed milk dry substance 70.0-77.3 Rapeseed oil 51.6-57.0 Palm olein oil 51.6-57.0 Whey protein concentrate dry substance rich in phospholipids 497-550 Sunflower oil 38, 3-42.3 Dry matter from sweet whey 34.5-38.1 Sunflower oil with high oleic acid content 24.9-27.6 Minerals 16.1-17.8 N atrium caseinate 4.92-5.44 Lecithin powder 4.26-4 , 70 Arachidonic acid oil 1.60-3.50 Docosahexaenoic acid oil 1.60-2.17 Vitamin mixture 1.29-1.43 Choline, taurine, myo-inositol, L-carnitine 1.21-1.34 Examples of preparation methods according to the invention, which do not limit the scope of the invention: Preparation method for a nutrient composition in powder form according to the invention: Milk-based raw materials i.a. ndas to a slurry. Standard milk or milk powder and fl surface whey or whey powder are mixed, if necessary with additional water. Appropriate equipment mixes the slurry in a negative pressure tank to reduce foaming and air entrainment. 27 10 15 20 25 30 536 599 Emulsifiers and fat-soluble vitamins are added to a mixture of vegetable oils.
The fat phase is then added to the milk phase either in the mixing tank or inline-dosed before homogenization. Inline dosing of oil means that part of the milk phase is heated, oil is dosed in the fate of the milk phase, homogenized and cooled down again.
Water-soluble vitamins, additives such as taurine and minerals with prooxidative effect such as iron and copper salts are added just before the slurry is concentrated by means of a finisher to a final dry matter content of 50-55%. The concentrate is then heat treated to ensure the microbiological quality and spray dried, the powder is cooled and stored. After quality control, the product is packaged or, if it is a semi-finished product, mixed first, combining the spray-dried semi-finished product with additional minerals, vitamins, bioactive components and citric acid.
Preparation method for a ready-to-drink nutritional composition according to the invention: Water made basic with calcium hydroxide is mixed with whey or whey powder.
The solution is neutralized before adding the carbohydrate source and standardized milk. Additional ingredients such as choline, taurine, inositol and carnitine are added prior to pasteurization, fat phase induction and homogenization. The fat phase consists of vegetable oils, emulsifiers and fat-soluble vitamins. Before sterilization, vitamins are added and quality control is performed. The product is UHT-treated, a rapid heat treatment at about 140 ° C for 5 seconds, cooled and packaged aseptically.
(UHT stands for Ultra High Temperature. Products from a UHT process have good durability with retained nutritional values.) Below is an example of the nutritional composition according to the invention and also a description of a control composition, both of which are used in a comparative study. The following examples of the invention do not limit the scope of the invention: The infant formula A composition used in the study is an example of a nutritional composition according to the invention. The control composition is used for comparison. The comparative control composition is a conventional infant formula of good quality that is available on the market.
The infant formulas included in the study have the following compositions, see table below. The composition is an example of the composition according to the invention: 28 536 599 _ Control composition _ _ Composition A __ _ Definitive composition (kg / 1,000 kg) ( kg / 1,000 kg) Lactose 502 536 Cream dry substance 130 89.6 105 Skimmed milk dry substance 73.7 Rapeseed oil 54.3 43.4 Palm olein oil 54.3 75.9 Whey protein concentrate dry matter 52.4 (rich in phospholipids) Sunflower oil 40.3 30.7 Dry substance from sweet whey 36.3 61.1 Sunflower oil with high oleic acid content 26.3 30.7 Minerals 17.0 10.1 Sodium caseinate 5.18 6.56 Lecithin powder 4.48 4.03 Arachidonic acid oil 3.33 2.91 Docosahexaenoic acid oil 2, 07 1.80 Vitamin mixture 1.38 1.48 Choline, taurine, myo-inositol, L-carnitine 1.27 1.04 L-arginine 0.689 Potassium citrate 4.68 2.58 Calcium carbonate 3.33 3.33 29 536 599 Potassium chloride 3.08 2.19 Calcium hydrogen phosphate 1.94 Magnesium sulphate 1.78 0.583 N atrial chloride 1.40 0.972 Ascorbic acid 1.08 1.22 Choline chloride 0.648 0.486 N atrial citrate 0, 500 Taurine 0.415 0.370 J ferrous sulphate 0.178 0.150 Myo-inositol 0.135 0.120 Zinc sulphate 0.0863 0.0769 Ascorbyl palmitate 0.0782 0.0751 L-carnitine 0.0756 0.0656 Vitamin D3 0.0539 0.0480 Vitamin A 0.0476 0 , 0424 DL-α-tocopherol 0.0350 0.0362 Calcium D-pantothenate 0.0296 0.0263 Niacin 0.0180 0.0160 Copper sulphate 0.00846 0.00754 Thiamine hydrochloride 0.00676 0.00602 Vitamin K1 0.00561 0 , 00500 Pyridoxine hydrochloride 0.00546 0.00486 Potassium iodide 0.00073 0.00073 30 10 15 20 25 536 599 Folic acid o, ooo62 o, ooo55 Sodium selenite o, ooo39 o, ooo39 Biotin o, ooo11 o, ooo1o Composition A, which is a nutritional composition according to the invention, with the ingredients described above, contains the nutritional values presented below as ready for consumption (114 g of composition Ai powdered form is mixed with 900 ml of water to give 1,000 ml of ready-to-drink product): The control composition, with the ingredients described above, contains the nutritional values presented below as ready for consumption (130 g - a total energy content of 60 kcal / 100 ml, - a protein content of 1,2 g / 100 ml, - an energy content of protein of 8,0% (E%) of the total energy content of the nutrient composition - a fat content which is 52,5% (E% ) of the total energy content of the nutrient composition according to composition A, - a content of fatty acids with medium carbon chains (comprising 8 to 10 carbon atoms) of 1,6% by weight of the total amount of fatty acid composition A, - a sialic acid content of 19 mg / 100 ml, - a cholesterol content of 8 mg / 100 ml, - lipid-bound sialic acid as gangliosides with 4% by weight of the total sialic acid content. control composition in powder form is mixed with 900 ml of water to give 1 000 ml of ready-to-drink product): - a total energy content of 66 kcal / 100 ml, - a protein content of 1,27 g / 100 ml, - an energy content of protein of 7,7 % (E%), of the total energy content of the nutrient composition according to the control composition, 31 10 15 20 25 536 599 - a fat content of 44,7% (E%), of the total energy content of the nutrient composition according to the control composition, - a content of fatty acids with medium carbon chains (including 8 to 10 carbon atoms) of 1,5% by weight of the total amount of fatty acids in the control composition, - a sialic acid content of 16 mg / 100 ml, - a cholesterol content of 4 mg / 100 ml, - lipid-bound sialic acid as gangliosides with 2% by weight of the total sialic acid content according to the control composition.
Study Design design The study is a randomized double-blind intervention trial with infants who are only breastfed as a reference group, which means that three groups of children participate in the study: 1) Children who are breastfed. 2) Children receiving a modified infant formula, "composition A", according to the invention (see description above). 3) Children who receive a conventional infant formula of good quality, in this presentation called "control composition" (see description above).
Group size The study is designed to be able to detect a possible difference corresponding to 0.5 standard deviations (SD) for each outcome variable, which corresponds to a weight difference of about 0.4 kg at 6 months of age or a difference of 3.25 percent body fat measured by plethysmography at 2 months of age. In visual acuity, 0.5 SD corresponds to 0.25 octaves at 4 months of age, which is the difference seen when comparing children who have received infant formula with or without DHA. With a statistical "power" of 80%, a group size of just over 60 children is needed. 80 children will be included in each group, which will provide a sufficient number of children per group completing the study.
Infants included in the study 32 10 15 20 25 30 536 599 Infants with a birth weight between 2,500 g and 4,500 g, and whose parents intend to breastfeed for only 6 months or whose parents only give breast milk compensation from the time they start participating in the study ( maximum 2 months after birth), is recruited partly via the pediatric clinic at Umeå University, and partly via a telephone survey (about infant breeding) to all parents whose children were 1 month old. The age at the beginning of participation in the study was 0-2 months.
Exclusion criteria Children with chronic diseases that may affect the outcome variables, such as neurological or endocrine disease, or malabsorption, are excluded from the study. Even children who for various reasons cannot complete the intervention will be monitored and included in the statistical analysis according to the principle "intention to treat".
Stratification, randomization and blinded trials All groups are stratified for gender so that the three groups all consist of half boys, half fl girls. Children receiving infant formula are randomized, divided by gender, into blocks of 8 to "composition A" (a composition according to the invention) and "control composition" respectively.
Outcome parameters The children will be followed from inclusion to 1 year of age with blood, saliva and stool samples as well as other examinations; see below. The study is divided into two parts. The first part of the study runs from inclusion until the age of 12 months, and the second part at the age of 5 years.
Growth Growth is measured both by classical anthropometry and by measuring body composition with air-displacement plethysmography (PEA POD). In most previous studies of infant growth, height, weight and head circumference have been observed. With these methods, it is not possible to determine whether a weight gain is due to muscle / organ growth or an increase in adipose tissue. To evaluate risk factors and interventions that affect growth, it is important to be able to measure body composition. With plethysmography, you can in a validated way measure the percentage of fat mass and fat-free mass in the body. This provides insight into the quality of growth. An infant given the infant formula (Composition A) is believed to have a growth similar to that of breastfed infants. 33 10 15 20 25 536 599 Insulin resistance Insulin sensitivity is calculated using HOMA, which is a mathematical model that uses fasting insulin (mIU / l) and blood sugar (mmol / l) to calculate insulin sensitivity.
Fixed values for infants are not the same as for adults. In the study, the "fasting stomach" is at least 2 hours after the last food intake.
Total intima-media thickness IMT in the vascular vein enicarotis communis The total thickness of the intima-media (IMT) in the vessel wall in the carotid communis, as well as the abdominal aorta is measured (mm) with ultrasound. Increased IMT in the carotid artery is a precursor to atherosclerosis and indicates future risk of cardiovascular disease. In children with obesity at the age of 8-9 years, there is an increase in carotid IMT, which is reversible after a successful procedure.
IMT in the aorta in neonates with intrauterine growth retardation is greater than in normal control groups, as well as in children of smoking mothers. In addition to ultrasound measurements, β-homocysteine (umol / l) is measured because β-homocysteine was correlated with IMT in a study of children with family is hypercholesterolemia.
Inhalation parameters As markers for the intestinal immunological development, the development of the normal intestinal flora and inflammatory parameters such as: calprotectin / f (mg / kg), highly sensitive CRP, IL-6 and IL-10 are monitored.
Microbiological parameters The bacterial spectrum in faeces (pyrosequence) is measured. Additional microbiological testing of the oral cavity will be performed using PCR (Polymerase Chain Reaction) technology.
Saliva Sialic acid will be measured in saliva.
Blood urea nitrogen (BUN) test and plasma amino acids BUN test is a measure of the amount of nitrogen in the blood in the form of urea (mg / dl). The levels are affected by the efficiency of kidney function. BUN concentrations may be elevated when there is more protein in the diet.
Blood samples are taken to measure patterns in plasma amino acids (mg / dl). 34 10 15 20 25 536 599 Insulin-like growth factor 1, leptin and adiponectin Insulin-like growth factor 1 (IGF-1) is measured. Increased insulin secretion and IGF-1 stimulation may contribute to increased BMI caused by high protein intake in infancy.
Leptin and adiponectin will be measured.
Measurements Cholesterol (LDL / HDL) (mmol / l), apolipoprotein A-1 / B are measured, as well as the fatty acid profile in red blood cells (RBC). Markers for sphingomyelin are documented.
Metabolomics Metabolomics are studies of the metabolites that are the result of cellular metabolism.
Metabolomics will be used to record specific metabolic differences between breastfed infants and those receiving infant formula, which could lead to interesting hypotheses.
Development The development of the nervous system can be measured with greater precision the older the child is. At 6 months of age, vision development is used as a measure of the maturity of the nervous system. Visual acuity and contrast sensitivity are measured with "Swept Visual Evoked Potential" (SWEEP-VEP). In individual children, SWEEP-VEP can be misleading, but when studying groups, it is a reliable method of estimating vision development.
At 12 months of age, an age-appropriate test of cognitive and psychomotor development is performed with the Bayley Scales of Infant Development (BSID-II). At the age of 5, a cognitive test is performed again, this time with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-R).
Maternal control To measure "maternal control", a simple form with six questions is used, which is a modified version of the CFQ (Child Feeding Questionnaire), adapted for one-year-old children. At 4 months of age, a similarly adapted form is used that is suitable for infants who are breastfed and for those who receive infant formula.
Diet documentation 35 10 536 599 Diet diary is kept for 3 consecutive days, every month from inclusion to 6 months of age for the children in the two groups who receive infant formula.
Morbidity Symptom diary is kept continuously from time to inclusion. The frequency and consistency of the stool is registered until 6 months of age, days with infection symptoms (fever> 38 degrees, runny nose, cough, vomiting, diarrhea) are registered until 12 months of age.
Results The new nutritional composition according to the invention reduces the differences between infants who are breastfed and those who receive the nutritional composition according to the invention in terms of growth and metabolic factors, susceptibility to infection and neurological development. 36

权利要求:
Claims (1)
[1]
A composition of nutrition, as a ready-to-use product or a ready-to-use product reconstituted with water from a prepared powder, wherein the total energy content is 62 kcal / 100 ml or less, and the composition comprises: - a protein content which is 1,25 g / 100 ml or less, - an energy content from protein of 7.8-8.4 percent of the total energy content of the nutrient composition. - an energy content from fat which is at least 50% or more of the total energy content of the nutrient composition - a content of fatty acids with medium carbon chains comprising 8 to 10 carbon atoms which is less than 3% by weight of the total amount of fatty acids, - a sialic acid content of 10-25 mg / 100 ml or higher, - a cholesterol content of 5-10 mg / 100 ml. The nutritional composition of claim 1 wherein the composition further comprises lipid-bound sialic acid as gangliosides and wherein the content of lipid-bound sialic acid as gangliosides is 1.5-5% by weight or 4% by weight of the total sialic acid content. Nutrient composition according to any one of the preceding claims wherein the cholesterol content is 0.2-0.3% by weight of the total fat content in said nutritional composition or 0.23% by weight of the total fat content. Nutrient composition according to any one of the preceding claims wherein the cholesterol content is 7-9 mg / 100 ml or 8 mg / 100 ml. A nutritional composition according to any one of the preceding claims wherein said cholesterol is milk cholesterol. Nutrient composition according to any one of the preceding claims wherein the energy content of protein is 8.0-8.3% of the total energy content of the nutrient composition. A nutritional composition according to any one of the preceding claims wherein the content of medium chain fatty acids (comprising 8 to 10 carbon atoms) is less than 2% or between 1%. -3% or between 1-2% of the total amount of fatty acids. Nutrient composition according to any one of the preceding claims, wherein the energy content of fat is 50-54% of the total energy content of the nutritional composition or 52-53% of the total energy content of the composition. A nutritional composition according to any one of the preceding claims wherein the composition further has a non-protein nitrogen (NPN) value of 0.015-0.20 g / 100 ml. Nutrient composition according to any one of the preceding claims, wherein the energy content of the nutrient composition is 58-62 kcal / 100 ml or, for example, 58-60 kcal / 100 ml. A nutritional composition according to any one of the preceding claims wherein the protein content of the nutritional composition is 1.1-1.25 g / 100 ml or between 1.1 g / 100 ml and less than 1.25 g / 100 ml. Nutrient composition according to any one of the preceding claims wherein the sialic acid content is 18-20 mg / 100 ml. A nutritional composition according to any one of the preceding claims wherein the composition comprises a composition enriched in whey protein concentrate dry substance rich in phospholipids at 5-6% by weight of said total dry powder composition. A nutritional composition according to any one of the preceding claims wherein the composition comprises intact or partially hydrolysed milk protein. Nutrient composition according to any one of the preceding claims, wherein the amino acid content of the composition is derived from milk powder, whey powder from sweet whey, casein powder and cream powder, and whey protein concentrate rich in phospholipids. A nutritional composition according to any one of the preceding claims wherein said composition further comprises sangomyelin, and wherein the content of sangomyelin in the composition of the invention is 9 mg / 100 ml or higher, or 9-15 mg / 100 ml, or 13 mg / 100 ml. Nutritional composition according to any one of the preceding claims wherein the cholesterol content is 7-10 mg / 100 ml or 8 mg / 100 ml. Nutrient composition according to any one of the preceding claims comprising: - dry matter from sweet whey, 32-40 kg / 1,000 kg dry powder composition or 32.6-39.9 kg / 1,000 kg dry powder composition, - sodium caseinate, 4.6-5.7 kg / 1,000 kg dry powder composition or 4,66-5,69 kg / 1,000 kg dry powder composition, - skimmed milk powder, 66-81 kg / 1,000 kg dry powder composition or 66,3- 81 kg / 1,000 kg dry powder composition, - whey protein concentrate dry substance rich in phospholipids, 47-58 kg / 1,000 kg dry powder composition or 47.1-57.6 kg / 1,000 kg dry powder composition, - cream dry substance, 117-143 kg / 1,000 kg dry powder composition. Nutrient composition according to any one of the preceding claims wherein the composition comprises: dry whey dry matter with 36.3 kg / 1,000 kg dry powder composition, sodium caseinate with 5.18 kg / 1,000 kg dry powder composition, skim milk dry matter with 73.7 kg / 1,000 kg dry powder composition, whey powder composition rich in phospholipids with 52.4 kg / 1,000 kg dry powder composition, sour cream substance with 130 kg / 1,000 kg dry powder composition. Nutrient composition according to any one of claims 18-19, wherein kg / 1,000 kg of powder is the same as kg / 8,770 l of potable nutritional composition. Use of a nutritional composition according to any one of the preceding claims as a infant formula or as a supplementary industry. Use of a nutritional composition according to any one of the preceding claims as a nutritional composition to provide a developmental and / or growth pattern and / or morbidity more similar to data for breastfed infants and / or for parameters which are one or more of growth, body composition in weight percent fat , cholesterol level, blood urea nitrogen (BUN), saline sialic acid, levels of fasting insulin or reduced risk of childhood obesity, insulin resistance, total thickness of intima and media (IMT) in the vessel wall over the carotid artery 39 10 15 20 25 30 23. 24. 25. 536 599 and abdominal aorta, inhalation parameters, microbiological parameters, plasma amino acids, IGF-1, dietary intake. A nutritional composition according to any one of claims 1-20, or use according to any one of claims 21-22, wherein the composition is a powder suitable for preparing a surfactant composition after reconstitution with water. A nutritional composition according to any one of claims 1-22 wherein said powder preparation is effected by mixing 114 g of nutritional composition powder with 900 ml of water to produce a 1,000 ml surface composition according to the invention. Method for preparing a nutritional composition according to the present invention for obtaining a high sialic acid content and a high cholesterol content in combination with a low protein and energy content, comprising the following steps: - to provide ingredients per 1,000 kg of powder or per 8,770 l of ready-to-drink nutritional composition comprising: 26. - dry matter from sweet whey, 32-40 kg / 1 000 kg dry powder composition or per 8 770 l potable nutritional composition, - sodium caseinate, 4,6-5,7 kg / 1 000 kg dry powder composition or per 8 770 l potable nutritional composition, - skimmed milk solids, 66-81 kg / 1 ooo kg dry powder composition or per 8 770 l potable nutrient composition, - whey protein concentrate dry matter rich in phospholipids, 47-58 kg / 1,000 kg dry powder composition or per 8 7701 potable nutrient composition / composition, 000 kg dry powder composition or per 8 770 l ready-to-drink nutritional composition, - in addition further including, for example, vitamins, minerals, fats, lactose and other essential nutrients (eg choline, taurine, inositol, carnitine, nucleotides), and - mixing the ingredients. A method of preparing a nutritional composition according to claim 25 wherein no free amino acids are added in addition to naturally occurring free amino acids found in dairy products. 40

类似技术:

---

公开号 | 公开日 | 专利标题

---

SE536599C2|2014-03-18|Nutritional composition with low calorie and low protein content

---

Hernell et al.2016|Clinical benefits of milk fat globule membranes for infants and children

---

AU2002357354B2|2008-11-20|Infant formula compositions comprising increased amounts of alpha-lactalbumin

---

TWI332399B|2010-11-01|Nutritional composition for controlling blood sugar level

---

JP2009542226A|2009-12-03|Enhanced infant formula

---

PT2096941E|2012-04-11|Nutritional composition for infants

---

CN105188411A|2015-12-23|Method of enhancing bioavailability of DHA and other lipid-soluble nutrients

---

JP6609555B2|2019-11-20|Brain function improving agent and preventive or therapeutic agent for cognitive impairment

---

US7651716B2|2010-01-26|Methods for reducing adverse effects of feeding formula to infants

---

US9889162B2|2018-02-13|Prophylactic use for prevention of infections

---

TW201507627A|2015-03-01|Nutritional composition comprising whey and hydrolyzed casein and uses thereof

---

JP4307475B2|2009-08-05|Infant nutrition composition

---

RU2290822C2|2007-01-10|Product for enteral feeding

---

WO2021086255A1|2021-05-06|Nutritional composition comprising milk and egg phospholipids

---

RU2639450C1|2017-12-21|Method for feeding of infants with mucoviscidosis

---

WO2021094241A1|2021-05-20|USE OF α-LACTALBUMIN ENRICHED WHEY PROTEIN EXTRACT AS A SOURCE OF CHOLESTEROL

---

WO2021257543A1|2021-12-23|Nutritional formula

---

JP2000060424A|2000-02-29|Infant food composition adjusted with phospholipid and fatty acid composition

---

RU2440767C1|2012-01-27|Sterilised dairy product based on goat milk for pregnant and nursing women alimentation

---

JP2001231496A|2001-08-28|Nutritive composition

同族专利:

---

公开号 | 公开日

---

US20150079225A1|2015-03-19|

---

CN104411184A|2015-03-11|

---

EP3942944A1|2022-01-26|

---

LT3590358T|2021-11-10|

---

ES2624541T3|2017-07-14|

---

EP2836084B1|2016-12-21|

---

EP2836084A2|2015-02-18|

---

PT2836084T|2017-03-16|

---

LT3175719T|2019-11-25|

---

CN107259527B|2020-12-11|

---

DK3590358T3|2021-10-18|

---

PT3590358T|2021-10-21|

---

LT2836084T|2017-03-27|

---

CN107518410A|2017-12-29|

---

ES2894886T3|2022-02-16|

---

WO2013153071A2|2013-10-17|

---

US20170013869A1|2017-01-19|

---

EP3590358A1|2020-01-08|

---

SE536599C3|2017-01-10|

---

SE1250357A1|2013-10-11|

---

ES2757404T3|2020-04-29|

---

RU2014139123A|2016-05-27|

---

EP3590358B1|2021-08-11|

---

CN104411184B|2017-09-12|

---

RU2617606C2|2017-04-25|

---

DK3175719T3|2019-11-11|

---

DK2836084T3|2017-03-20|

---

CN107259527A|2017-10-20|

---

PT3175719T|2019-11-25|

---

WO2013153071A3|2013-11-28|

---

EP3175719B1|2019-09-04|

---

EP3175719A1|2017-06-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

IT1049516B|1970-07-23|1981-02-10|Erba Carlo Spa|DIETETIC PRODUCT THAT CAN BE USED AS A PHYSIOLOGICAL CORRECTOR FOR VACCINE MILK AND PROCEDURE FOR ITS MANUFACTURE|

---

JP3137268B2|1991-05-20|2001-02-19|明治乳業株式会社|Dairy products containing high cholesterol|

---

AU2003297323A1|2002-12-23|2004-07-22|Bausch And Lomb Incorporated|Surface treatment utilizing microwave radiation|

---

US20050175759A1|2004-02-09|2005-08-11|Atul Singhal|Newborn infant formulas and feeding methods|

---

US7951410B2|2003-04-14|2011-05-31|Mead Johnson Nutrition Company|Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid|

---

US7867541B2|2003-04-14|2011-01-11|Mead Johnson Nutrition Company|Compositions and methods of formulation for enteral formulas containing sialic acid|

---

CN1842277A|2003-06-24|2006-10-04|堪萨斯大学医学中心|Infant formula|

---

DE602005026456D1|2004-12-27|2011-03-31|Nestec Sa|USE OF INFANT FOOD WITH REDUCED PROTEIN CONTENT|

---

AU2006327996B2|2005-12-23|2012-03-29|N.V. Nutricia|Infant nutritional compositions for preventing obesity|

---

AT509624T|2005-12-23|2011-06-15|Nutricia Nv|COMPOSITION COMPRISING MULTIPLE UNSATURATED FATTY ACIDS, PROTEINS, MANGANESE AND / OR MOLYBDES AND NUCLEOTIDES / NUCLEOSIDES, FOR THE TREATMENT OF DEMENTIA|

---

MY148280A|2006-03-23|2013-03-29|Nutricia Nv|Preterm formula|

---

US20080003330A1|2006-06-30|2008-01-03|Ricardo Rueda|Infant formulas for early brain development|

---

US20080003329A1|2006-06-30|2008-01-03|Ricardo Rueda|Enriched infant formulas|

---

WO2008054192A1|2006-11-02|2008-05-08|N.V. Nutricia|Use of nutritional compositions for preventing disorders|

---

EP1932437A1|2006-12-15|2008-06-18|Nestec S.A.|Infant formula|

---

KR20090097945A|2006-12-28|2009-09-16|메이지 데어리즈 코포레이션|Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same|

---

PL2211629T3|2007-10-19|2020-11-16|Fonterra Co-Operative Group Limited|Methods of maintaining or increasing growth or cognitive development|

---

US20110009359A1|2007-12-21|2011-01-13|N.V. Nutricia|Use of non-digestible carbohydrates for improving intestinal microbiota|

---

FR2930406B1|2008-04-29|2011-04-15|Groupe Lactalis|CHILD-BASED INFANT FEED OF MILK ORIGIN|

---

EA011075B1|2008-06-20|2008-12-30|Лев Михайлович МОГИЛЕВСКИЙ|Dry powdered milk formula|

---

PT2341784E|2008-09-02|2013-02-11|Nutricia Nv|Nutritional compositions with coated lipid globules|

---

EP2258218A1|2009-06-02|2010-12-08|Nestec S.A.|Nutritional Composition for Supporting Brain Development and Function of Toddlers|

---

WO2011115476A1|2010-03-17|2011-09-22|N.V. Nutricia|Infant nutrition for improving fatty acid composition of brain membranes later in life|

---

WO2012173467A1|2011-06-16|2012-12-20|N.V. Nutricia|Metabolic imprinting effects of specifically designed lipid component|

---

WO2013036102A1|2011-09-08|2013-03-14|N.V. Nutricia|Use of infant formula with cholesterol|

---

SE536599C3|2012-04-10|2017-01-10|Hero Ag|Nutritional composition with low calorie and low protein content|

---

WO2014058301A1|2012-10-12|2014-04-17|N.V. Nutricia|Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life|WO2011115476A1|2010-03-17|2011-09-22|N.V. Nutricia|Infant nutrition for improving fatty acid composition of brain membranes later in life|

---

SE536599C3|2012-04-10|2017-01-10|Hero Ag|Nutritional composition with low calorie and low protein content|

---

SE537951C2|2013-07-01|2015-12-01|Hero Ag|Prophylactic use of infant formula for otitis|

---

CA2926599C|2013-11-05|2021-05-04|Hill's Pet Nutrition, Inc.|Methods and compositions for improving kidney function|

---

EP3082462A1|2013-11-29|2016-10-26|Nestec S.A.|Nutritional compositions with phospholipids|

---

AU2014361230B2|2013-12-12|2018-09-06|Société des Produits Nestlé S.A.|Synthetic milk compositions for infants less than three months old and for infants and children more than three months for ensuring optimal growth and preventing obesity|

---

CN105979799A|2013-12-13|2016-09-28|雀巢产品技术援助有限公司|Use of a sweet whey containing infant formula for promoting the postnatal neuronal development of the infant gastrointestinal tract, and the establishment of the intestinal functions that it controls|

---

US20160366916A1|2015-06-18|2016-12-22|Cambrooke Therapeutics, Inc.|Formula for management of phenylketonuria|

---

EP3340810B1|2015-08-27|2020-12-16|Société des Produits Nestlé S.A.|Synthetic nutritional compositions tailored for infants of specific ages, and nutritional systems comprising them|

---

AU2016310560A1|2015-08-27|2018-01-18|Société des Produits Nestlé S.A.|Gender specific synthetic nutritional compositions and nutritional systems comprising them|

---

US20180296481A1|2015-10-15|2018-10-18|N.V. Nutricia|Infant formula with special lipid architecture for promoting healthy growth|

---

EP3362061A1|2015-10-15|2018-08-22|N.V. Nutricia|Infant formula with milk fat for promoting healthy growth|

---

WO2017102720A1|2015-12-14|2017-06-22|Nestec S.A.|Nutritional compositions and infant formulas to promote myelination in the brain|

---

AU2016374160A1|2015-12-14|2018-04-19|Société des Produits Nestlé S.A.|Nutritional composition and infant formula for promoting de novo myelination|

---

EP3435787A1|2016-03-30|2019-02-06|Nestec S.A.|Nutritional compositions and their use|

---

WO2018104512A1|2016-12-09|2018-06-14|N.V. Nutricia|Nutritional composition for improving cell membranes|

---

WO2018138620A1|2017-01-29|2018-08-02|Gupta Samit|Ketogenic nutritional composition and preparation method thereof|

---

EP3618645A1|2017-05-03|2020-03-11|Société des Produits Nestlé S.A.|Whey protein extracts and their use as sphingomyelin source|

---

RU2668400C1|2017-05-10|2018-09-28|федеральное государственное бюджетное образовательное учреждение высшего образования "Вологодская государственная молочнохозяйственная академия имени Н.В. Верещагина" |Method of manufacture of dairy concentrated product with sugar|

---

DE102018112898A1|2018-05-30|2019-12-05|Westfälische Wilhelms-Universität Münster|Edible cholesterol-containing emulsions|

---

EP3646739A1|2018-11-01|2020-05-06|N.V. Nutricia|Nutritional composition comprising urea and non-digestible oligosaccharides|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

SE1250357A|SE536599C3|2012-04-10|2012-04-10|Nutritional composition with low calorie and low protein content|SE1250357A| SE536599C3|2012-04-10|2012-04-10|Nutritional composition with low calorie and low protein content|

---

EP21190407.3A| EP3942944A1|2012-04-10|2013-04-09|A nutritional composition|

---

LT16205569T| LT3175719T|2012-04-10|2013-04-09|A nutritional composition|

---

RU2014139123A| RU2617606C2|2012-04-10|2013-04-09|Food composition|

---

LTEP13720266.9T| LT2836084T|2012-04-10|2013-04-09|A nutritional composition|

---

CN201710338105.1A| CN107259527B|2012-04-10|2013-04-09|Nutritional composition|

---

PT137202669T| PT2836084T|2012-04-10|2013-04-09|A nutritional composition|

---

EP19193193.0A| EP3590358B1|2012-04-10|2013-04-09|A nutritional composition|

---

EP16205569.3A| EP3175719B1|2012-04-10|2013-04-09|A nutritional composition|

---

LTEP19193193.0T| LT3590358T|2012-04-10|2013-04-09|A nutritional composition|

---

ES19193193T| ES2894886T3|2012-04-10|2013-04-09|Nutritional composition|

---

CN201380025927.4A| CN104411184B|2012-04-10|2013-04-09|Alimentation composition|

---

EP13720266.9A| EP2836084B1|2012-04-10|2013-04-09|A nutritional composition|

---

PT191931930T| PT3590358T|2012-04-10|2013-04-09|A nutritional composition|

---

ES13720266.9T| ES2624541T3|2012-04-10|2013-04-09|Nutritional composition|

---

PT162055693T| PT3175719T|2012-04-10|2013-04-09|A nutritional composition|

---

DK16205569T| DK3175719T3|2012-04-10|2013-04-09|FOOD COMPOSITION|

---

US14/391,494| US20150079225A1|2012-04-10|2013-04-09|Nutritional composition|

---

DK13720266.9T| DK2836084T3|2012-04-10|2013-04-09|FOOD COMPOSITION|

---

DK19193193.0T| DK3590358T3|2012-04-10|2013-04-09|FOOD COMPOSITION|

---

PCT/EP2013/057405| WO2013153071A2|2012-04-10|2013-04-09|A nutritional composition|

---

CN201710695706.8A| CN107518410A|2012-04-10|2013-04-09|Alimentation composition|

---

ES16205569T| ES2757404T3|2012-04-10|2013-04-09|Nutritional composition|

---

US15/244,304| US20170013869A1|2012-04-10|2016-08-23|Nutritional composition|